Luye Pharma Group Ltd.
LYPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.15 | -3.69 | 0.05 |
| FCF Yield | 24.71% | -12.15% | -3.90% | 2.39% |
| EV / EBITDA | 12.11 | 11.84 | 17.28 | 13.81 |
| Quality | ||||
| ROIC | 1.71% | 1.60% | 2.26% | 2.53% |
| Gross Margin | 67.83% | 65.81% | 67.60% | 69.80% |
| Cash Conversion Ratio | 5.70 | 1.25 | -1.02 | 2.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.13% | 0.85% | 0.16% | 1.69% |
| Free Cash Flow Growth | 255.66% | -190.65% | -244.41% | 168.50% |
| Safety | ||||
| Net Debt / EBITDA | 4.92 | 4.30 | 6.51 | 2.69 |
| Interest Coverage | 0.00 | 1.13 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.17 | 1.12 | 1.22 | 1.18 |
| Cash Conversion Cycle | 117.91 | 149.21 | 104.37 | 71.02 |